Bücher Wenner
Olga Grjasnowa liest aus "JULI, AUGUST, SEPTEMBER
04.02.2025 um 19:30 Uhr
Atypical Antipsychotics: Road to Metabolic Toxicity
von Soban Sadiq, Naseer Ahmed
Verlag: LAP LAMBERT Academic Publishing
Hardcover
ISBN: 9786139839759
Erschienen am 24.05.2018
Sprache: Englisch
Format: 220 mm [H] x 150 mm [B] x 9 mm [T]
Gewicht: 238 Gramm
Umfang: 148 Seiten

Preis: 44,90 €
keine Versandkosten (Inland)


Dieser Titel wird erst bei Bestellung gedruckt. Eintreffen bei uns daher ca. am 18. November.

Der Versand innerhalb der Stadt erfolgt in Regel am gleichen Tag.
Der Versand nach außerhalb dauert mit Post/DHL meistens 1-2 Tage.

44,90 €
merken
klimaneutral
Der Verlag produziert nach eigener Angabe noch nicht klimaneutral bzw. kompensiert die CO2-Emissionen aus der Produktion nicht. Daher übernehmen wir diese Kompensation durch finanzielle Förderung entsprechender Projekte. Mehr Details finden Sie in unserer Klimabilanz.
Klappentext
Biografische Anmerkung

Atypical antipsychotics are commonly prescribed for the treatment of several psychiatric disorders including schizophrenia and psychosis. However prolong use leads to severe metabolic side effects such as weight gain, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, dyslipidemia and essential hypertension. These metabolic abnormalities lead to an increased cardiovascular diseases.According to various studies the prevalence of antipsychotic related metabolic adverse reactions vary from 23 to 50% -two-three fold higher than general population.It is therefore necessary to find the underlying mechanism by which atypical antipsychotics cause metabolic toxicity. This book basically provides review encompassing schizophrenia, its underlying cause, atypical antipsychotic use and its role in causing metabolic toxicity. It also covers role of adipose tissue and adipocytokines in metabolic toxicity.This review should be useful for professionals in pharmaceutical industry and research students in Universities.



Soban e Naseer têm um interesse especial em Farmacologia Clínica, incluindo toxicidades metabólicas. Ambos publicaram numerosos artigos em revistas locais e internacionais. Atualmente, ambos estão a trabalhar com universidades europeias e indústrias farmacêuticas para desenvolver medicamentos que serão utilizados no tratamento de toxicidades cardiovasculares.